• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SD filed by Henry Schein Inc.

    5/30/25 4:18:14 PM ET
    $HSIC
    Medical Specialities
    Health Care
    Get the next $HSIC alert in real time by email
    SD 1 formsdconflictmineral.htm FORM SD 2024 formsdconflictmineral
     
     
     
     
     
     
    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
    FORM SD
    Specialized Disclosure Report
    HENRY SCHEIN, INC.
    (Exact name of registrant as specified in its charter)
    DELAWARE
    0-27078
    11-3136595
    (State or other jurisdiction
    (Commission File
    (IRS Employer
    of incorporation)
    Number)
    Identification No.)
    135 DURYEA ROAD, MELVILLE,
     
    NEW YORK
    11747
    (Address of principal executive offices)
    (Zip Code)
    Kelly Murphy, Senior Vice
     
    President and General Counsel
    (631) 843-5500
    (Name and telephone number, including area code, of the person to contact in connection with this report.)
    Check the appropriate box to indicate the rule pursuant to which this form is being filed, and
    provide the period to which the information in this form applies:
     
    [X] Rule 13p-1 under the Securities Exchange Act (17 CFR 240.13p-1) for the reporting period
    from January 1, 2024 to December 31, 2024.
     
    Section 1 – Conflict Minerals Disclosure
    Item 1.01.
     
    Conflict Minerals Disclosure and Report
    Conflict Minerals Disclosure
    This disclosure for the calendar year ended December 31, 2024 is presented to comply with Rule
    13p-1 under the Securities Exchange Act of 1934 (the “Rule”).
     
    The Rule imposes certain
    reporting obligations on Securities and Exchange Commission registrants whose manufactured
    products contain conflict minerals which are necessary to the functionality or production of their
    products. Conflict Minerals are defined as cassiterite, columbite-tantalite, gold, wolframite, and
    their derivatives, which are limited to tin, tantalum, and tungsten.
     
    These requirements apply to
    registrants whatever the geographic origin of the Conflict Minerals and whether or not they fund
    armed conflict.
    If a registrant conducts a Reasonable Country of Origin Inquiry (“RCOI”) and determines that
    the conflict minerals originated from sources other than the Democratic Republic of the Congo
    or an adjoining country (the “Covered Countries”), or from recycled and scrap sources, they are
    required only to submit a Form SD, which describes the RCOI.
    Although a substantial percentage of the products we sell are purchased from third-party
    suppliers as finished products, we manufacture or contract with third parties to manufacture a
    portion of our product portfolio.
     
    We determined that certain of those products contain Conflict
    Minerals that are necessary to their functionality or production.
     
    To determine if the Conflict Minerals in our manufactured and other covered products originated
    from sources in the Covered Countries, we conducted a RCOI in good faith.
     
    We surveyed all
    known suppliers from whom we purchase materials containing the Conflict Minerals and
    reviewed the available public websites of such known suppliers.
     
    We also utilized the
     
    Responsible Minerals Initiative’s Conflict Minerals Reporting Template
     
    (CMRT) to obtain the
    relevant data.
     
    The responses to our inquiry and results of our review can be grouped into the two categories
    identified below:
    ●
    The supplier represented that its products do not contain Conflict Minerals from the
    Covered Countries.
    ●
    The supplier represented that its products contain Conflict Minerals from the Covered
    Countries but they have implemented reasonable due diligence measures and
    practices to ensure responsible sourcing (
    e.g.
    , participate in Conflict-Free Smelter
    Program assessment protocols).
    As a result of our RCOI, we have no reason to believe that our necessary Conflict Minerals (i)
    may have originated in the Covered Countries or (ii) if they originated in the Covered Countries,
    failed to meet conflict-free sourcing or the Conflict-Free Smelter Program assessment protocols.
    This Form SD is publicly available at investor.henryschein.com.
     
    The website and information
    accessible through it are not incorporated into this document.
    Item 1.02.
     
    Exhibit
    Not applicable.
    Section 2 – Exhibits
    Item 2.01.
     
    Exhibits
    Not applicable.
     
     
    SIGNATURE
    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly
    caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
    HENRY SCHEIN, INC.
    By: /s/ KELLY
     
    MURPHY
    Kelly Murphy
    Senior Vice President and General Counsel
    Dated: May 30, 2025
    Get the next $HSIC alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $HSIC

    DatePrice TargetRatingAnalyst
    7/14/2025$72.00Outperform → Neutral
    Robert W. Baird
    2/14/2025$80.00Equal Weight
    Wells Fargo
    1/6/2025$69.00 → $84.00Underperform → Buy
    BofA Securities
    12/4/2024$75.00Neutral
    Mizuho
    7/22/2024$81.00 → $92.00Neutral → Outperform
    Robert W. Baird
    2/26/2024$78.00Market Perform
    Leerink Partners
    12/12/2023$71.00 → $82.00Neutral → Overweight
    JP Morgan
    11/10/2023$70.00Hold → Buy
    Stifel
    More analyst ratings

    $HSIC
    SEC Filings

    See more
    • SEC Form 8-K filed by Henry Schein Inc.

      8-K - HENRY SCHEIN INC (0001000228) (Filer)

      7/15/25 7:10:41 AM ET
      $HSIC
      Medical Specialities
      Health Care
    • SEC Form 11-K filed by Henry Schein Inc.

      11-K - HENRY SCHEIN INC (0001000228) (Filer)

      6/20/25 8:01:34 AM ET
      $HSIC
      Medical Specialities
      Health Care
    • Henry Schein Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement

      8-K - HENRY SCHEIN INC (0001000228) (Filer)

      6/9/25 8:30:38 AM ET
      $HSIC
      Medical Specialities
      Health Care

    $HSIC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Large owner Kkr Hawaii Aggregator L.P.

      4 - HENRY SCHEIN INC (0001000228) (Issuer)

      6/18/25 7:24:32 PM ET
      $HSIC
      Medical Specialities
      Health Care
    • Chairman, CEO Bergman Stanley M gifted 145 units of Common Stock par value $0.01 per shre, decreasing direct ownership by 0.04% to 323,747 units (SEC Form 4)

      4 - HENRY SCHEIN INC (0001000228) (Issuer)

      6/17/25 4:36:56 PM ET
      $HSIC
      Medical Specialities
      Health Care
    • Director Daniel William K was granted 2,849 shares (SEC Form 4)

      4 - HENRY SCHEIN INC (0001000228) (Issuer)

      6/16/25 5:36:46 PM ET
      $HSIC
      Medical Specialities
      Health Care

    $HSIC
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Henry Schein downgraded by Robert W. Baird with a new price target

      Robert W. Baird downgraded Henry Schein from Outperform to Neutral and set a new price target of $72.00

      7/14/25 8:40:13 AM ET
      $HSIC
      Medical Specialities
      Health Care
    • Wells Fargo initiated coverage on Henry Schein with a new price target

      Wells Fargo initiated coverage of Henry Schein with a rating of Equal Weight and set a new price target of $80.00

      2/14/25 7:05:26 AM ET
      $HSIC
      Medical Specialities
      Health Care
    • Henry Schein upgraded by BofA Securities with a new price target

      BofA Securities upgraded Henry Schein from Underperform to Buy and set a new price target of $84.00 from $69.00 previously

      1/6/25 8:12:21 AM ET
      $HSIC
      Medical Specialities
      Health Care

    $HSIC
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Henry Schein to Webcast Second Quarter 2025 Conference Call on Tuesday, August 5, 2025, at 8:00 a.m. ET

      Henry Schein, Inc. (NASDAQ:HSIC), the world's largest provider of health care solutions to office-based dental and medical practitioners, announced today that it will release its second quarter 2025 financial results before the stock market opens on Tuesday, August 5, 2025, and will provide a live webcast of its earnings conference call on the same day beginning at 8:00 a.m. Eastern time. Speakers on the call will include Stanley M. Bergman, Chairman of the Board and Chief Executive Officer of Henry Schein, and Ronald N. South, Senior Vice President and Chief Financial Officer. Investors can access the call by visiting https://investor.henryschein.com/webcasts. A replay will be available

      7/22/25 6:30:00 AM ET
      $HSIC
      Medical Specialities
      Health Care
    • Stanley M. Bergman to Retire as Henry Schein's Chief Executive Officer at the End of 2025

      Mr. Bergman to Continue to Serve as Chairman of the Board Henry Schein, Inc. (NASDAQ:HSIC), the world's largest provider of health care solutions to office-based dental and medical practitioners, announced today that Stanley M. Bergman will retire as Chief Executive Officer (CEO) at the end of the year after 45 years at the Company, including more than 35 years as CEO. Mr. Bergman will continue to lead Henry Schein in his current role until his retirement and will remain as Chairman thereafter. The Board is commencing a formal search process in conjunction with a nationally recognized executive search firm and will consider internal and external candidates. "With the progress made advan

      7/15/25 7:05:00 AM ET
      $HSIC
      Medical Specialities
      Health Care
    • Updated: Henry Schein to Participate in Upcoming Investor Conference in June

      Henry Schein, Inc., the world's largest provider of health care solutions to office-based dental and medical practitioners, announced today that the Company will present at the following investor conference in June: Jefferies Global Healthcare Conference at the Marriott Marquis hotel, New York City, on June 4, at 12:50 p.m. Eastern time. Henry Schein's presentations can be heard via live webcast by visiting www.henryschein.com/IRwebcasts. Replays will be available on the Henry Schein website following the presentations. About Henry Schein, Inc. Henry Schein, Inc. (NASDAQ:HSIC) is a solutions company for health care professionals powered by a network of people and technology. With ap

      6/2/25 6:45:00 PM ET
      $HSIC
      Medical Specialities
      Health Care

    $HSIC
    Leadership Updates

    Live Leadership Updates

    See more
    • Stanley M. Bergman to Retire as Henry Schein's Chief Executive Officer at the End of 2025

      Mr. Bergman to Continue to Serve as Chairman of the Board Henry Schein, Inc. (NASDAQ:HSIC), the world's largest provider of health care solutions to office-based dental and medical practitioners, announced today that Stanley M. Bergman will retire as Chief Executive Officer (CEO) at the end of the year after 45 years at the Company, including more than 35 years as CEO. Mr. Bergman will continue to lead Henry Schein in his current role until his retirement and will remain as Chairman thereafter. The Board is commencing a formal search process in conjunction with a nationally recognized executive search firm and will consider internal and external candidates. "With the progress made advan

      7/15/25 7:05:00 AM ET
      $HSIC
      Medical Specialities
      Health Care
    • Henry Schein Announces Completion of Strategic Investment by KKR and Appointment of Dan Daniel to Board of Directors

      Henry Schein, Inc. (NASDAQ:HSIC), the world's largest provider of health care solutions to office-based dental and medical practitioners, today announced the successful completion of a $250 million strategic investment by funds affiliated with KKR, a leading global investment firm. Upon the closing of this transaction, KKR has become the holder of approximately 12% of the common shares of Henry Schein. In connection with the investment, William K. "Dan" Daniel, Executive Advisor to KKR and former Executive Vice President of Danaher Corporation, has officially joined Henry Schein's Board of Directors as an independent director. He joins Max Lin, Partner at KKR and leader of the firm's Healt

      5/16/25 4:10:00 PM ET
      $HSIC
      $KKR
      Medical Specialities
      Health Care
      Investment Managers
      Finance
    • PureTech Founded Entity Seaport Therapeutics Appoints Robert J. Hombach to its Board of Directors as Audit Committee Chair

      Former Baxter and Baxalta Chief Financial Officer brings more than 30 years of biotech financial and operational experience PureTech Health plc (NASDAQ:PRTC, LSE: PRTC)) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company, noted that its Founded Entity, Seaport Therapeutics, ("Seaport") a clinical-stage biopharmaceutical company that is advancing novel neuropsychiatric medicines with a proven strategy and team, today announced that Robert "Bob" J. Hombach has been appointed to its Board of Directors and will serve as the Chair of the Audit Committee. Mr. Hombach is a seasoned financial and operational executive with three decades of high-level leadership in the healthca

      3/11/25 7:05:00 AM ET
      $BAX
      $BMRN
      $EMBC
      $HSIC
      Medical/Dental Instruments
      Health Care
      Biotechnology: Pharmaceutical Preparations
      Medical Specialities

    $HSIC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Henry Schein Inc.

      SC 13G/A - HENRY SCHEIN INC (0001000228) (Subject)

      11/13/24 3:30:01 PM ET
      $HSIC
      Medical Specialities
      Health Care
    • SEC Form SC 13G filed by Henry Schein Inc.

      SC 13G - HENRY SCHEIN INC (0001000228) (Subject)

      11/12/24 9:32:27 AM ET
      $HSIC
      Medical Specialities
      Health Care
    • SEC Form SC 13G/A filed by Henry Schein Inc. (Amendment)

      SC 13G/A - HENRY SCHEIN INC (0001000228) (Subject)

      2/14/24 11:18:57 AM ET
      $HSIC
      Medical Specialities
      Health Care

    $HSIC
    Financials

    Live finance-specific insights

    See more
    • Henry Schein to Webcast Second Quarter 2025 Conference Call on Tuesday, August 5, 2025, at 8:00 a.m. ET

      Henry Schein, Inc. (NASDAQ:HSIC), the world's largest provider of health care solutions to office-based dental and medical practitioners, announced today that it will release its second quarter 2025 financial results before the stock market opens on Tuesday, August 5, 2025, and will provide a live webcast of its earnings conference call on the same day beginning at 8:00 a.m. Eastern time. Speakers on the call will include Stanley M. Bergman, Chairman of the Board and Chief Executive Officer of Henry Schein, and Ronald N. South, Senior Vice President and Chief Financial Officer. Investors can access the call by visiting https://investor.henryschein.com/webcasts. A replay will be available

      7/22/25 6:30:00 AM ET
      $HSIC
      Medical Specialities
      Health Care
    • Henry Schein Reports First Quarter 2025 Financial Results

      First-quarter 2025 GAAP diluted EPS of $0.88, growth of 22% compared to the first quarter of 2024 First-quarter 2025 non-GAAP diluted EPS of $1.15, growth of 4.5% compared to the first quarter of 2024 Maintains guidance for 2025 non-GAAP diluted EPS of $4.80 to $4.94, mid-single digit 2025 Adjusted EBITDA growth, and sales growth of 2% to 4% Repurchased $161 million of common stock, or approximately 2.3 million shares Henry Schein, Inc. (NASDAQ:HSIC), the world's largest provider of health care solutions to office-based dental and medical practitioners, today reported financial results for the first quarter ended March 29, 2025. "We are pleased with our first quarter financial re

      5/5/25 6:00:00 AM ET
      $HSIC
      Medical Specialities
      Health Care
    • Henry Schein to Webcast First Quarter 2025 Conference Call on Monday, May 5th, 2025, at 8:00 a.m. ET

      Henry Schein, Inc. (NASDAQ:HSIC), the world's largest provider of health care solutions to office-based dental and medical practitioners, announced today that it will release its first quarter 2025 financial results before the stock market opens on Monday, May 5th, 2025, and will provide a live webcast of its earnings conference call on the same day beginning at 8:00 a.m. Eastern time. Speakers on the call will include Stanley M. Bergman, Chairman of the Board and Chief Executive Officer of Henry Schein, and Ronald N. South, Senior Vice President and Chief Financial Officer. Investors can access the call by visiting https://investor.henryschein.com/webcasts. A replay will be available on

      4/8/25 6:30:00 AM ET
      $HSIC
      Medical Specialities
      Health Care